A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä

Extragonadal FSHR Expression and Function—Is It Real?




TekijätChrusciel Marcin, Ponikwicka-Tyszko Donata, Wolczynski Slawomir, Huhtaniemi Ilpo, Rahman Nafis A.

KustantajaFRONTIERS MEDIA SA

Julkaisuvuosi2019

JournalFrontiers in Endocrinology

Tietokannassa oleva lehden nimiFRONTIERS IN ENDOCRINOLOGY

Lehden akronyymiFRONT ENDOCRINOL

Artikkelin numeroARTN 32

Vuosikerta10

Sivujen määrä10

ISSN1664-2392

DOIhttps://doi.org/10.3389/fendo.2019.00032

Verkko-osoitehttps://www.frontiersin.org/articles/10.3389/fendo.2019.00032/full

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/39605996


Tiivistelmä
Expression of the follicle-stimulating hormone receptor (FSHR), besides gonadal tissues, has recently been detected in several extragonadal normal and tumorous tissues, including different types of primary and metastatic cancer and tumor vessel endothelial cells (TVEC). The suggested FSH actions in extragonadal tissues include promotion of angiogenesis, myometrial contractility, skeletal integrity, and adipose tissue accumulation. Non-malignant cells within cancer tissue have been shown to be devoid of FSHR expression, which implies a potential role of FSHR as a diagnostic, prognostic, or even a therapeutic tool. There are shared issues between several of the published reports questioning the validity of some of the conclusion. Firstly, protein expression of FSHR was performed solely with immunohistochemistry (IHC) using either an unavailable "in house" FSHR323 monoclonal antibody or poorly validated polyclonal antibodies, usually without additional methodological quality control and confirmations. Secondly, there is discrepancy between the hardly traceable or absent FSHR gene amplification/transcript data and non-reciprocal strong FSHR protein immunoreactivity. Thirdly, the pharmacological high doses of recombinant FSH used in in vitro studies also jeopardizes the physiological or pathophysiological meaning of the findings. We performed in this review a critical analysis of the results presenting extragonadal expression of FSHR and FSH action, and provide a rationale for the validation of the reported results using additional more accurate and sensitive supplemental methods, including in vivo models and proper positive and negative controls.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 17:17